Astellas Pharma

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, headquartered in Tokyo, Japan. The company was established on April 1, 2005, through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Astellas is involved in the research, development, manufacture, import, and export of pharmaceuticals.

History

The history of Astellas Pharma Inc. is marked by the merger of two leading Japanese pharmaceutical companies, Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. The merger was aimed at creating a more robust entity capable of competing on the global market.

Business Operations

Astellas Pharma Inc. operates in over 70 countries worldwide. The company's primary areas of focus include oncology, immunology, urology, and neuroscience. Astellas is also involved in the development of pharmaceuticals for infectious diseases and cardiovascular diseases.

Research and Development

Astellas Pharma Inc. has a strong commitment to research and development. The company's R&D efforts are focused on creating innovative drugs that can contribute to the health of patients around the world. Astellas has research facilities in Japan, North America, and Europe.

Products

Some of the key products of Astellas Pharma Inc. include Prograf, a drug used to prevent organ rejection in transplant patients, and Xtandi, a drug used to treat prostate cancer. The company also manufactures Vesicare, a drug used to treat overactive bladder.

Corporate Social Responsibility

Astellas Pharma Inc. is committed to fulfilling its corporate social responsibility through various initiatives. These include efforts to improve access to medicines, promote health education, and contribute to the sustainable development of society.

See Also

• Pharmaceutical industry in Japan
• List of pharmaceutical companies

External Links

• Official Website

‎